AstraZeneca Q3 pre-tax profit up, product sales downStaff Writer | November 9, 2017
AstraZeneca reported that its third-quarter profit before tax increased 10 percent to $746 million from $676 million last year.
AstraZeneca Core earnings per share were $1.12
Core earnings per share were $1.12, down 15 percent. Core operating profit increased 9 percent to $1.85 billion.
Total revenue was $6.23 billion, up 9 percent from $5.70 billion last year. Revenues grew 10 percent on a constant exchange rate.
Product Sales, meanwhile, dropped 3 percent to $4.88 billion.
Looking ahead, for fiscal 2017, the company now anticipates a 2017 Core earnings per share performance towards the favourable end of the guidance range of a low to mid teens percentage decline.
Total revenue for the year is still expected to a low to mid single-digit percentage decline. ■